Clinical Lung Cancer publishes study: 93% of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test
OncoHost announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer (NSCLC) patients.
Choosing the appropriate first-line therapy for metastatic NSCLC remains complex, with the role of new biomarkers in clinical practice still being explored. The study, “Impact of PROphet Test in Changing Physicians’ Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small Cell Lung Cancer,” examines how the PROphetNSCLC test, a plasma proteomics machine learning-based assay, influences oncologists’ treatment choices for these patients.
The study found that incorporating PROphetNSCLC with PD-L1 expression significantly affected therapeutic decisions. PROphetNSCLC provides additional insights to identify patients who may benefit from various treatment options, including ICI monotherapy, combination therapy, or chemotherapy, which may help optimize treatment effectiveness and reduce toxicity.
In the study, 100 oncologists reviewed three virtual metastatic NSCLC cases with PD-L1 scores and recommended a first-line regimen. After an educational session on the PROphetNSCLC test, they re-evaluated the same cases with PROphet results, leading to notable changes in treatment recommendations.
